Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 401956, 14 pages
http://dx.doi.org/10.1155/2015/401956
Research Article

The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling

1Pharmacokinetics, Dynamics and Metabolism-New Biological Entities, Pfizer, Andover, MA 01810, USA
2Pharmacokinetics, Dynamics and Metabolism-New Biological Entities, Pfizer, Cambridge, MA 02138, USA
3Pharmacokinetics, Dynamics and Metabolism-New Biological Entities, Pfizer, San Diego, CA 92121, USA

Received 31 July 2015; Accepted 7 October 2015

Academic Editor: Marzio Pennisi

Copyright © 2015 Liusong Yin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. S. Dimitrov, “Therapeutic proteins,” in Therapeutic Proteins, vol. 899 of Methods in Molecular Biology, pp. 1–26, Humana Press, 2012. View at Publisher · View at Google Scholar
  2. G. Walsh, “Biopharmaceutical benchmarks 2014,” Nature Biotechnology, vol. 32, no. 10, pp. 992–1000, 2014. View at Publisher · View at Google Scholar
  3. V. Brinks, D. Weinbuch, M. Baker et al., “Preclinical models used for immunogenicity prediction of therapeutic proteins,” Pharmaceutical Research, vol. 30, no. 7, pp. 1719–1728, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. R. T. Purcell and R. F. Lockey, “Immunologic responses to therapeutic biologic agents,” Journal of Investigational Allergology & Clinical Immunology, vol. 18, no. 5, pp. 335–342, 2008. View at Google Scholar · View at Scopus
  5. V. Jawa, L. P. Cousens, M. Awwad, E. Wakshull, H. Kropshofer, and A. S. De Groot, “T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation,” Clinical Immunology, vol. 149, no. 3, pp. 534–555, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. J. R. Maneiro, E. Salgado, and J. J. Gomez-Reino, “Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis,” JAMA Internal Medicine, vol. 173, no. 15, pp. 1416–1428, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. P. A. van Schouwenburg, T. Rispens, and G. J. Wolbink, “Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis,” Nature Reviews Rheumatology, vol. 9, no. 3, pp. 164–172, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Shankar, S. Arkin, L. Cocea et al., “Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides—harmonized terminology and tactical recommendations,” The AAPS Journal, vol. 16, no. 4, pp. 658–673, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. A. S. De Groot and D. W. Scott, “Immunogenicity of protein therapeutics,” Trends in Immunology, vol. 28, no. 11, pp. 482–490, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. S. K. Singh, “Impact of product-related factors on immunogenicity of biotherapeutics,” Journal of Pharmaceutical Sciences, vol. 100, no. 2, pp. 354–387, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Krieckaert, T. Rispens, and G. Wolbink, “Immunogenicity of biological therapeutics: from assay to patient,” Current Opinion in Rheumatology, vol. 24, no. 3, pp. 306–311, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Sethu, K. Govindappa, M. Alhaidari, M. Pirmohamed, K. Park, and J. Sathish, “Immunogenicity to biologics: mechanisms, prediction and reduction,” Archivum Immunologiae et Therapiae Experimentalis, vol. 60, no. 5, pp. 331–344, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. A. C. Moss, V. Brinks, and J. F. Carpenter, “Review article: immunogenicity of anti-TNF biologics in IBD—the role of patient, product and prescriber factors,” Alimentary Pharmacology & Therapeutics, vol. 38, no. 10, pp. 1188–1197, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Kumar, S. K. Singh, X. Wang, B. Rup, and D. Gill, “Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions,” Pharmaceutical Research, vol. 28, no. 5, pp. 949–961, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Kumar, M. A. Mitchell, B. Rup, and S. K. Singh, “Relationship between potential aggregation-prone regions and HLA-DR-binding T-cell immune epitopes: implications for rational design of novel and follow-on therapeutic antibodies,” Journal of Pharmaceutical Sciences, vol. 101, no. 8, pp. 2686–2701, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. K. D. Ratanji, J. P. Derrick, R. J. Dearman, and I. Kimber, “Immunogenicity of therapeutic proteins: influence of aggregation,” Journal of Immunotoxicology, vol. 11, no. 2, pp. 99–109, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Sauerborn, V. Brinks, W. Jiskoot, and H. Schellekens, “Immunological mechanism underlying the immune response to recombinant human protein therapeutics,” Trends in Pharmacological Sciences, vol. 31, no. 2, pp. 53–59, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Hermeling, L. Aranha, J. M. A. Damen et al., “Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b,” Pharmaceutical Research, vol. 22, no. 12, pp. 1997–2006, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Hermeling, H. Schellekens, C. Maas, M. F. B. G. Gebbink, D. J. A. Crommelin, and W. Jiskoot, “Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation,” Journal of Pharmaceutical Sciences, vol. 95, no. 5, pp. 1084–1096, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Human, H. Ilsley, C. Roberson et al., “Assessment of the immunogenicity of mechanically induced interferon aggregates in a transgenic mouse model,” Journal of Pharmaceutical Sciences, vol. 104, no. 2, pp. 722–730, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. V. Filipe, W. Jiskoot, A. H. Basmeleh, A. Halim, H. Schellekens, and V. Brinks, “Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice,” mAbs, vol. 4, no. 6, pp. 740–752, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. M. K. Joubert, M. Hokom, C. Eakin et al., “Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses,” The Journal of Biological Chemistry, vol. 287, no. 30, pp. 25266–25279, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. A. J. Freitag, M. Shomali, S. Michalakis et al., “Investigation of the immunogenicity of different types of aggregates of a murine monoclonal antibody in mice,” Pharmaceutical Research, vol. 32, no. 2, pp. 430–444, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Seidl, O. Hainzl, M. Richter et al., “Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity,” Pharmaceutical Research, vol. 29, no. 6, pp. 1454–1467, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. V. S. Purohit, C. R. Middaugh, and S. V. Balasubramanian, “Influence of aggregation on immunogenicity of recombinant human factor VIII in hemophilia A mice,” Journal of Pharmaceutical Sciences, vol. 95, no. 2, pp. 358–371, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. D. S. Pisal, M. P. Kosloski, C. R. Middaugh, R. B. Bankert, and S. V. Balu-Iyer, “Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice,” Journal of Pharmaceutical Sciences, vol. 101, no. 6, pp. 2055–2065, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. M. M. C. van Beers, M. Sauerborn, F. Gilli, V. Brinks, H. Schellekens, and W. Jiskoot, “Aggregated recombinant human interferon beta induces antibodies but no memory in immune-tolerant transgenic mice,” Pharmaceutical Research, vol. 27, no. 9, pp. 1812–1824, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. A. H. Fradkin, J. F. Carpenter, and T. W. Randolph, “Glass particles as an adjuvant: a model for adverse immunogenicity of therapeutic proteins,” Journal of Pharmaceutical Sciences, vol. 100, no. 11, pp. 4953–4964, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. J. G. Barnard, K. Babcock, and J. F. Carpenter, “Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity,” Journal of Pharmaceutical Sciences, vol. 102, no. 3, pp. 915–928, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. V. Rombach-Riegraf, A. C. Karle, B. Wolf et al., “Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro,” PLoS ONE, vol. 9, no. 1, Article ID e86322, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Lundegaard, O. Lund, C. Keşmir, S. Brunak, and M. Nielsen, “Modeling the adaptive immune system: predictions and simulations,” Bioinformatics, vol. 23, no. 24, pp. 3265–3275, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. J. D. Gómez-Mantilla, I. F. Trocóniz, Z. Parra-Guillén, and M. J. Garrido, “Review on modeling anti-antibody responses to monoclonal antibodies,” Journal of Pharmacokinetics and Pharmacodynamics, vol. 41, no. 5, pp. 523–536, 2014. View at Publisher · View at Google Scholar
  33. T. P. Hickling, X. Chen, P. Vicini, and S. Nayak, “A review of quantitative modeling of B cell responses to antigenic challenge,” Journal of Pharmacokinetics and Pharmacodynamics, vol. 41, no. 5, pp. 445–459, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Palsson, T. P. Hickling, E. L. Bradshaw-Pierce et al., “The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models,” BMC Systems Biology, vol. 7, article 95, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. N. G. B. Agrawal and J. J. Linderman, “Mathematical modeling of helper T lymphocyte/antigen-presenting cell interactions: analysis of methods for modifying antigen processing and presentation,” Journal of Theoretical Biology, vol. 182, no. 4, pp. 487–504, 1996. View at Publisher · View at Google Scholar · View at Scopus
  36. G. I. Bell, “Mathematical model of clonal selection and antibody production,” Journal of Theoretical Biology, vol. 29, no. 2, pp. 191–232, 1970. View at Publisher · View at Google Scholar · View at Scopus
  37. K. B. Blyuss and L. B. Nicholson, “The role of tunable activation thresholds in the dynamics of autoimmunity,” Journal of Theoretical Biology, vol. 308, pp. 45–55, 2012. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  38. K. B. Blyuss and L. B. Nicholson, “Understanding the roles of activation threshold and infections in the dynamics of autoimmune disease,” Journal of Theoretical Biology, vol. 375, pp. 13–20, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Oprea and A. S. Perelson, “Exploring the mechanisms of primary antibody responses to T cell-dependent antigens,” Journal of Theoretical Biology, vol. 181, no. 3, pp. 215–236, 1996. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Rundell, R. DeCarlo, H. HogenEsch, and P. Doerschuk, “The humoral immune response to Haemophilus influenzae type b: a mathematical model based on T-zone and germinal center B-cell dynamics,” Journal of Theoretical Biology, vol. 194, no. 3, pp. 341–381, 1998. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Castiglione, F. Toschi, M. Bernaschi et al., “Computational modeling of the immune response to tumor antigens,” Journal of Theoretical Biology, vol. 237, no. 4, pp. 390–400, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Y. Lee, D. J. Topham, S. Y. Park et al., “Simulation and prediction of the adaptive immune response to influenza A virus infection,” Journal of Virology, vol. 83, no. 14, pp. 7151–7165, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. S. M. Ciupe, R. M. Ribeiro, and A. S. Perelson, “Antibody responses during hepatitis B viral infection,” PLoS Computational Biology, vol. 10, no. 7, Article ID e1003730, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. B. Sulzer and A. S. Perelson, “Equilibrium binding of multivalent ligands to cells: effects of cell and receptor density,” Mathematical Biosciences, vol. 135, no. 2, pp. 147–185, 1996. View at Publisher · View at Google Scholar · View at Scopus
  45. B. Sulzer and A. S. Perelson, “Immunons revisited: binding of multivalent antigens to b cells,” Molecular Immunology, vol. 34, no. 1, pp. 63–74, 1997. View at Publisher · View at Google Scholar · View at Scopus
  46. X. Chen, T. Hickling, E. Kraynov, B. Kuang, C. Parng, and P. Vicini, “A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics,” The AAPS Journal, vol. 15, no. 4, pp. 1141–1154, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. X. Chen, T. P. Hickling, and P. Vicini, “A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 2—model applications,” CPT: Pharmacometrics & Systems Pharmacology, vol. 3, no. 9, article e134, 10 pages, 2014. View at Publisher · View at Google Scholar
  48. X. Chen, T. P. Hickling, and P. Vicini, “A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 1—theoretical model,” CPT: Pharmacometrics & Systems Pharmacology, vol. 3, no. 9, pp. 1–9, 2014. View at Publisher · View at Google Scholar
  49. S. E. Grossberg, J. Oger, L. D. Grossberg, A. Gehchan, and J. P. Klein, “Frequency and magnitude of interferon beta neutralizing antibodies in the evaluation of interferon beta immunogenicity in patients with multiple sclerosis,” Journal of Interferon & Cytokine Research, vol. 31, no. 3, pp. 337–344, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. L. O. Narhi, J. Schmit, K. Bechtold-Peters, and D. Sharma, “Classification of protein aggregates,” Journal of Pharmaceutical Sciences, vol. 101, no. 2, pp. 493–498, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Reth, “Matching cellular dimensions with molecular sizes,” Nature Immunology, vol. 14, no. 8, pp. 765–767, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Foote and H. N. Eisen, “Kinetic and affinity limits on antibodies produced during immune responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 5, pp. 1254–1256, 1995. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Foote and C. Milstein, “Kinetic maturation of an immune response,” Nature, vol. 352, no. 6335, pp. 530–532, 1991. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Crotty, P. Felgner, H. Davies, J. Glidewell, L. Villarreal, and R. Ahmed, “Cutting edge: long-term B cell memory in humans after smallpox vaccination,” The Journal of Immunology, vol. 171, no. 10, pp. 4969–4973, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. A. P. Kodituwakku, C. Jessup, H. Zola, and D. M. Roberton, “Isolation of antigen-specific B cells,” Immunology and Cell Biology, vol. 81, no. 3, pp. 163–170, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Ahmadi, C. J. Bryson, E. A. Cloake et al., “Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics,” Pharmaceutical Research, vol. 32, no. 4, pp. 1383–1394, 2015. View at Publisher · View at Google Scholar · View at Scopus
  57. C. Buelens, V. Verhasselt, D. De Groote, K. Thielemans, M. Goldman, and F. Willems, “Human dendritic cell responses to lipopolysaccharide and CD40 ligation are differentially regulated by interleukin-10,” European Journal of Immunology, vol. 27, no. 8, pp. 1848–1852, 1997. View at Publisher · View at Google Scholar · View at Scopus
  58. F. Granucci, E. Ferrero, M. Foti, D. Aggujaro, K. Vettoretto, and P. Ricciardi-Castagnoli, “Early events in dendritic cell maturation induced by LPS,” Microbes and Infection, vol. 1, no. 13, pp. 1079–1084, 1999. View at Publisher · View at Google Scholar · View at Scopus
  59. R. M. Cisco, Z. Abdel-Wahab, J. Dannull et al., “Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4,” Journal of Immunology, vol. 172, no. 11, pp. 7162–7168, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. K. Kawamura, K. Iyonaga, H. Ichiyasu, J. Nagano, M. Suga, and Y. Sasaki, “Differentiation, maturation, and survival of dendritic cells by osteopontin regulation,” Clinical and Diagnostic Laboratory Immunology, vol. 12, no. 1, pp. 206–212, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. Y.-C. Wang, X.-B. Hu, F. He et al., “Lipopolysaccharide-induced maturation of bone marrow-derived dendritic cells is regulated by notch signaling through the up-regulation of CXCR4,” The Journal of Biological Chemistry, vol. 284, no. 23, pp. 15993–16003, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. D. Verthelyi and V. Wang, “Trace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins,” PLoS ONE, vol. 5, no. 12, Article ID e15252, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Rossol, H. Heine, U. Meusch et al., “LPS-induced cytokine production in human monocytes and macrophages,” Critical Reviews in Immunology, vol. 31, no. 5, pp. 379–446, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. J. C. Jones, E. W. Settles, C. R. Brandt, and S. Schultz-Cherry, “Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine,” Vaccine, vol. 29, no. 44, pp. 7696–7703, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. L. Yin, J. M. Calvo-Calle, O. Dominguez-Amorocho, and L. J. Ster, “HLA-DM constrains epitope selection in the human CD4 T cell response to vaccinia virus by favoring the presentation of peptides with longer HLA-DM-mediated half-lives,” Journal of Immunology, vol. 189, no. 8, pp. 3983–3994, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. J. Bessa, S. Boeckle, H. Beck et al., “The immunogenicity of antibody aggregates in a novel transgenic mouse model,” Pharmaceutical Research, vol. 32, no. 7, pp. 2344–2359, 2015. View at Publisher · View at Google Scholar · View at Scopus
  67. W. Wang, “Protein aggregation and its inhibition in biopharmaceutics,” International Journal of Pharmaceutics, vol. 289, no. 1-2, pp. 1–30, 2005. View at Publisher · View at Google Scholar
  68. M. F. Bachmann and R. M. Zinkernagel, “Neutralizing antiviral B cell responses,” Annual Review of Immunology, vol. 15, pp. 235–270, 1997. View at Publisher · View at Google Scholar · View at Scopus
  69. E. Szomolanyi-Tsuda and R. M. Welsh, “T-cell-independent antiviral antibody responses,” Current Opinion in Immunology, vol. 10, no. 4, pp. 431–435, 1998. View at Publisher · View at Google Scholar · View at Scopus
  70. C. Babin, N. Majeau, and D. Leclerc, “Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP,” Journal of Nanobiotechnology, vol. 11, article 10, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. C. M. Snapper, T. M. McIntyre, R. Mandler et al., “Induction of IgG3 secretion by interferon γ: a model for T cell-independent class switching in response to T cell-independent type 2 antigens,” The Journal of Experimental Medicine, vol. 175, no. 5, pp. 1367–1371, 1992. View at Publisher · View at Google Scholar · View at Scopus
  72. T. Fehr, M. F. Bachmann, E. Bucher et al., “Role of repetitive antigen patterns for induction of antibodies against antibodies,” The Journal of Experimental Medicine, vol. 185, no. 10, pp. 1785–1792, 1997. View at Publisher · View at Google Scholar · View at Scopus
  73. P. K. A. Mongini, P. F. Highet, and J. K. Inman, “Human B cell activation: effect of T cell cytokines on the physicochemical binding requirements for achieving cell cycle progression via the membrane IgM signaling pathway,” Journal of Immunology, vol. 155, no. 7, pp. 3385–3400, 1995. View at Google Scholar · View at Scopus
  74. M. L. Wheeler, M. B. Dong, R. Brink, X.-P. Zhong, and A. L. DeFranco, “Diacylglycerol kinase zeta limits B cell antigen receptor-dependent activation of ERK Signaling to inhibit early antibody responses,” Science Signaling, vol. 6, no. 297, article ra91, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. G. G. B. Klaus, M. Holman, C. Johnson-Léger, J. R. Christenson, and M. R. Kehry, “Interaction of B cells with activated T cells reduces the threshold for CD40-mediated B cell activation,” International Immunology, vol. 11, no. 1, pp. 71–79, 1999. View at Publisher · View at Google Scholar · View at Scopus
  76. L. P. Kil, M. J. W. de Bruijn, M. van Nimwegen et al., “Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice,” Blood, vol. 119, no. 16, pp. 3744–3756, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. D. W. Scott and A. S. De Groot, “Can we prevent immunogenicity of human protein drugs?” Annals of the Rheumatic Diseases, vol. 69, supplement 1, pp. i72–i76, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. V. Brinks, W. Jiskoot, and H. Schellekens, “Immunogenicity of therapeutic proteins: the use of animal models,” Pharmaceutical Research, vol. 28, no. 10, pp. 2379–2385, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. L. Xue, M. Fiscella, M. Rajadhyaksha et al., “Pre-existing biotherapeutic-reactive antibodies: survey results within the american association of pharmaceutical scientists,” The AAPS Journal, vol. 15, no. 3, pp. 852–855, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. L. Xue and B. Rup, “Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics,” The AAPS Journal, vol. 15, no. 3, pp. 893–896, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. V. S. Sloan, P. Cameron, G. Porter et al., “Mediation by HLA-DM of dissociation of peptides from HLA-DR,” Nature, vol. 375, no. 6534, pp. 802–806, 1995. View at Publisher · View at Google Scholar · View at Scopus
  82. N. K. Nanda and A. J. Sant, “DM determines the cryptic and immunodominant fate of T cell epitopes,” The Journal of Experimental Medicine, vol. 192, no. 6, pp. 781–788, 2000. View at Publisher · View at Google Scholar · View at Scopus
  83. A. J. Sant, F. A. Chaves, S. A. Jenks et al., “The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II:peptide complexes,” Immunological Reviews, vol. 207, pp. 261–278, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. L. Yin, P. Trenh, A. Guce et al., “Susceptibility to HLA-DM protein is determined by a dynamic conformation of major histocompatibility complex class II molecule bound with peptide,” The Journal of Biological Chemistry, vol. 289, no. 34, pp. 23449–23464, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. K. R. Garrod, H. D. Moreau, Z. Garcia et al., “Dissecting T cell contraction in vivo using a genetically encoded reporter of apoptosis,” Cell Reports, vol. 2, no. 5, pp. 1438–1447, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. H. Lee, S. Haque, J. Nieto et al., “A p53 axis regulates B cell receptor-triggered, innate immune system-driven B cell clonal expansion,” Journal of Immunology, vol. 188, no. 12, pp. 6093–6108, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. C. L. M. Krieckaert, G. M. Bartelds, W. F. Lems, and G. J. Wolbink, “The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review,” Arthritis Research & Therapy, vol. 12, no. 5, article 217, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Radbruch, G. Muehlinghaus, E. O. Luger et al., “Competence and competition: the challenge of becoming a long-lived plasma cell,” Nature Reviews Immunology, vol. 6, no. 10, pp. 741–750, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. C. H. Rozanski, R. Arens, L. M. Carlson et al., “Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells,” The Journal of Experimental Medicine, vol. 208, no. 7, pp. 1435–1446, 2011. View at Publisher · View at Google Scholar · View at Scopus